No Detail Found!

Correlation of Peripheral Blood CD4/CD8 Ratio with E cacy and Prognosis in Patients with Non-Small Cell Lung Cancer Receiving PD-1/PD-L1 Inhibitors

Author(s)
Guo-Xiang Li Department of Thoracic Surgery, Central Hospital Affiliated to Shandong First Medical University, Jinan, China
Qi-Ming Zheng Department of Thoracic Surgery, Central Hospital Affiliated to Shandong First Medical University, Jinan, China;First Central Hospital of Tianjin Medical University, Tianjin Medical University, Tianjin, China
Yuan-Yuan Li Department of Oncology, Jinan Central Hospital, Shandong University, Jinan, China
Ye-Peng Wang Department of Neurosurgery, Central Hospital Affiliated to Shandong First Medical University, Jinan, China
Min Zhang Department of Dermatology, Central Hospital Affiliated to Shandong First Medical University, Jinan, China
Zhi-Gang Sun Department of Thoracic Surgery, Central Hospital Affiliated to Shandong First Medical University, Jinan, China
Abstract
The aim of this study was to investigate the predictive role of the peripheral blood CD4/CD8 ratio in patients with non-small cell lung cancer (NSCLC) treated with PD-1/PD-L1 inhibitors therapy. Cochrane, Embase, Medline, PubMed, and Web of Science were searched until November 2023. Data were analysed using Stata MP 17.0 software. Outcome indicators included progression-free survival (PFS) and overall survival (OS). A total of ve studies of the baseline CD4/CD8 ratio in peripheral blood strictly met the inclusion criteria. The pooled outcome indicator showed that high level of peripheral blood CD4/CD8 ratio in patients with NSCLC receiving PD-1/PD-L1 inhibitors was associated with better PFS (HR = 0.62, 95% CI: 0.49-0, 79, p <0.001), rather than OS (HR = 0.90, 95% CI: 0.53-1.51, p = 0.679). The results from this meta-analysis demonstrated that in patients with NSCLC receiving PD-1/PD-L1 inhibitors, a high baseline CD4/CD8 ratio in peripheral blood can predict better PFS.
Publication Details
Page(s) 800-802
Published Journal: Journal of the College of Physicians and Surgeons Pakistan, Volume: 35, Issue: 06, Year: 2025

Request the full text from PASTIC

Keywords
prognosis, Non-small Cell Lung Cancer, survival, Peripheral blood, Immune checkpoint inhibitors, CD4-CD8 Ratio
References
Du X,Wen S,Shi R,Xia J,Wang R,Zhang Y .2023 .Peripheral blood lymphocytes di erentiation patterns in responses/ outcomes to immune checkpoint blockade therapies in nonsmall cell lung cancer: A retrospective study. BMC Cancer, 10(1) : 83.
Li P,Qin P,Fu X,Zhang G,Yan X,Zhang M .2021 .Associations between peripheral blood lymphocyte subsets and clinical outcomes in patients with lung cancer treated with immune checkpoint inhibitor. Ann Palliat Med, 10(3) : 3039-49.
Lin X,Chen X,Long X,Zeng C,Zhang Z,Fang W .2023 .New biomarkers exploration and nomogram construction of prognostic and immune-related adverse events of advanced non-small cell lung cancer patients receiving immune checkpoint inhibitors. Respir Res, 10(1) : 64.
Xu X,Wang D,Chen W,Li N,Suwinski R,Rossi A .2021 .A nomogram model based on peripheral blood lymphocyte subsets to assess the prognosis of non-small cell lung cancer patients treated with immune checkpoint inhibitors. Transl Lung Cancer Res, 10(12) : 4511-25.
Yan Y,Wang X,Liu C,Jia J .2022 .Association of lymphocyte subsets with e cacy and prognosis of immune checkpoint inhibitor therapy in advanced non-small cell lung carcinoma: A retrospective study. BMCPulm Med, 10(1) : 166.
Uryvaev A,Passhak M,Hershkovits D,Sabo E,Sela GB .2018 .The role of tumor-in ltrating lymphocytes (TILs) as a predictive biomarker of response to anti-PD1 therapy in patients with metastatic non-small cell lung cancer or metastatic melanoma. Med Oncol, 10(3) : 25.
0

Citations

0

Downloads

107

Views